2C-G-5

2C-G-5 is a psychedelic drug and phenethylamine of the 2C family. It was first synthesized by Alexander Shulgin and is used for its psychoactive effects.

History[edit | edit source]

2C-G-5 was first synthesized by Alexander Shulgin. In his book PiHKAL, Shulgin lists the dosage as 20–35 mg and the duration as 18–30 hours. He describes 2C-G-5 as having a slow onset and a long duration of action, with the effects being extremely visual in nature.

Chemistry[edit | edit source]

2C-G-5 is a phenethylamine and 2C compound that is structurally related to other drugs of the 2C family, such as 2C-B and 2C-I. It is also structurally similar to mescaline, a naturally occurring psychedelic found in certain cacti.

The full name of the chemical is 2-(2,5-dimethoxy-3,4-dimethylphenyl)ethanamine. It has a molecular formula of C12H19NO2 and a molar mass of 209.29 g/mol.

Pharmacology[edit | edit source]

Like other 2C drugs, 2C-G-5 acts as a 5-HT2A receptor agonist. The 5-HT2A receptor is a subtype of the 5-HT2 receptor that resides in the central and peripheral nervous system and is primarily responsible for the cognitive effects of psychedelics.

Effects[edit | edit source]

The effects of 2C-G-5 are highly dose-dependent and can vary greatly among individuals. They can include visual hallucinations, changes in perception, euphoria, and altered thought processes. The onset of effects is slow, often taking several hours to become noticeable, and the duration of effects is long, often lasting up to 30 hours.

Legal status[edit | edit source]

The legal status of 2C-G-5 varies by country. In the United States, it is considered a Schedule I controlled substance under the Controlled Substances Act.

See also[edit | edit source]

Template:Psychedelic phenethylamines Template:Controlled substances

2C-G-5 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.